- Home
- RBOT vs SKYE Comparison
RBOT vs SKYE Comparison
Compare RBOT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | SKYE |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 44.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RBOT | SKYE |
|---|---|---|
| Price | $2.20 | $0.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.00 | ★ $14.75 |
| AVG Volume (30 Days) | 165.1K | ★ 263.7K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.20 | $0.99 |
| 52 Week High | $18.97 | $5.75 |
Technical Indicators
Market Signals| Indicator | RBOT | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 29.82 | 31.94 |
| Support Level | $2.36 | $1.04 |
| Resistance Level | $2.58 | $1.27 |
| Average True Range (ATR) | 0.30 | 0.10 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 2.00 | 4.55 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.